These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

125 related items for PubMed ID: 10446877

  • 21. Correction of neutropenia with rHuG-CSF after loss of response to rHuGM-CSF following autologous bone marrow transplant.
    Boulad F, Gillio A, Small TN, Bonilla MA, Philips P, Ruggiero M, Emanuel D, Ghavimi F, Kernan NA.
    Bone Marrow Transplant; 1994 May; 13(5):661-3. PubMed ID: 7519939
    [Abstract] [Full Text] [Related]

  • 22. Sustained G-CSF plasma levels following administration of pegfilgrastim fasten neutrophil reconstitution after high-dose chemotherapy and autologous blood stem cell transplantation in patients with multiple myeloma.
    Fenk R, Hieronimus N, Steidl U, Bruns I, Graef T, Zohren F, Ruf L, Haas R, Kobbe G.
    Exp Hematol; 2006 Oct; 34(10):1296-302. PubMed ID: 16982322
    [Abstract] [Full Text] [Related]

  • 23. Prospective randomized trial to evaluate two delayed granulocyte colony stimulating factor administration schedules after high-dose cytarabine therapy in adult patients with acute lymphoblastic leukemia.
    Hofmann WK, Seipelt G, Langenhan S, Reutzel R, Schott D, Schoeffski O, Illiger HJ, Hartmann F, Balleisen L, Franke A, Fiedler F, Huber C, Rasche H, Bergmann L, Ganser A, Pott C, Pasold R, Rudolph C, Ottmann OG, Gökbuget N, Hoelzer D.
    Ann Hematol; 2002 Oct; 81(10):570-4. PubMed ID: 12424538
    [Abstract] [Full Text] [Related]

  • 24. Glycosylated vs non-glycosylated granulocyte colony-stimulating factor (G-CSF)--results of a prospective randomised monocentre study.
    Bönig H, Silbermann S, Weller S, Kirschke R, Körholz D, Janssen G, Göbel U, Nürnberger W.
    Bone Marrow Transplant; 2001 Aug; 28(3):259-64. PubMed ID: 11535993
    [Abstract] [Full Text] [Related]

  • 25. Intensified-dose (4 gm/m2) cyclophosphamide and granulocyte colony-stimulating factor administration for hematopoietic stem cell mobilization in refractory rheumatoid arthritis.
    Breban M, Dougados M, Picard F, Zompi S, Marolleau JP, Bocaccio C, Heshmati F, Mezieres M, Dreyfus F, Bouscary D.
    Arthritis Rheum; 1999 Nov; 42(11):2275-80. PubMed ID: 10555020
    [Abstract] [Full Text] [Related]

  • 26. Adjunctive efficacy of granulocyte colony-stimulating factor on treatment of Pseudomonas aeruginosa pneumonia in neutropenic and non-neutropenic hosts.
    Babalola CP, Nightingale CH, Nicolau DP.
    J Antimicrob Chemother; 2004 Jun; 53(6):1098-100. PubMed ID: 15128727
    [Abstract] [Full Text] [Related]

  • 27. [Efficacy of once-per-cycle administration pegylated recombinant human granulocyte colony-stimulating factor in chemotherapy-induced neutropenia in a phase I trial].
    Yang S, Shi YK, Liu P, Han XH, He XH, Cai YM, Chen ZM.
    Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2006 Jun; 28(3):339-44. PubMed ID: 16900629
    [Abstract] [Full Text] [Related]

  • 28. Granulocyte-colony stimulating factor and multiple cycles of strongly myelosuppressive alkylator-based combination chemotherapy in children with neuroblastoma.
    Kushner BH, Heller G, Kramer K, Cheung NK.
    Cancer; 2000 Nov 15; 89(10):2122-30. PubMed ID: 11066054
    [Abstract] [Full Text] [Related]

  • 29. CD34+ dose-driven administration of granulocyte colony-stimulating factor after high-dose chemotherapy in lymphoma patients.
    Todisco E, Castagna L, Sarina B, Mazza R, Magagnoli M, Balzarotti M, Nozza A, Siracusano L, Timofeeva I, Anastasia A, Demarco M, Santoro A.
    Eur J Haematol; 2007 Feb 15; 78(2):111-6. PubMed ID: 17313558
    [Abstract] [Full Text] [Related]

  • 30. Limited versus severe Wegener's granulomatosis: baseline data on patients in the Wegener's granulomatosis etanercept trial.
    Stone JH, Wegener's Granulomatosis Etanercept Trial Research Group.
    Arthritis Rheum; 2003 Aug 15; 48(8):2299-309. PubMed ID: 12905485
    [Abstract] [Full Text] [Related]

  • 31. Urinary bladder cancer in Wegener's granulomatosis: risks and relation to cyclophosphamide.
    Knight A, Askling J, Granath F, Sparen P, Ekbom A.
    Ann Rheum Dis; 2004 Oct 15; 63(10):1307-11. PubMed ID: 15130900
    [Abstract] [Full Text] [Related]

  • 32. Solid malignancies among patients in the Wegener's Granulomatosis Etanercept Trial.
    Stone JH, Holbrook JT, Marriott MA, Tibbs AK, Sejismundo LP, Min YI, Specks U, Merkel PA, Spiera R, Davis JC, St Clair EW, McCune WJ, Ytterberg SR, Allen NB, Hoffman GS, Wegener's Granulomatosis Etanercept Trial Research Group.
    Arthritis Rheum; 2006 May 15; 54(5):1608-18. PubMed ID: 16646004
    [Abstract] [Full Text] [Related]

  • 33. Peripheral blood progenitor cell mobilization with intermediate-dose cyclophosphamide, sequential granulocyte-macrophage-colony-stimulating factor and granulocyte-colony-stimulating factor, and scheduled commencement of leukapheresis in 225 patients undergoing autologous transplantation.
    Bashey A, Donohue M, Liu L, Medina B, Corringham S, Ihasz A, Carrier E, Castro JE, Holman PR, Xu R, Law P, Ball ED, Lane TA.
    Transfusion; 2007 Nov 15; 47(11):2153-60. PubMed ID: 17958545
    [Abstract] [Full Text] [Related]

  • 34. Endogenous granulocyte colony-stimulating factor (G-CSF) levels in chemotherapy-induced neutropenia and in neutropenia related with primary diseases.
    Kavgaci H, Ozdemir F, Aydin F, Yavuz A, Yavuz M.
    J Exp Clin Cancer Res; 2002 Dec 15; 21(4):475-9. PubMed ID: 12636092
    [Abstract] [Full Text] [Related]

  • 35. Granulocyte-colony stimulating factor for the treatment of ritodrine-induced neutropenia.
    Kikkawa M, Matsubara S, Takatoku M, Kuwata T, Ohkuchi A, Izumi A, Watanabe T, Suzuki M.
    J Obstet Gynaecol Res; 2008 Apr 15; 34(2):286-90. PubMed ID: 18412800
    [Abstract] [Full Text] [Related]

  • 36. Etanercept combined with conventional treatment in Wegener's granulomatosis: a six-month open-label trial to evaluate safety.
    Stone JH, Uhlfelder ML, Hellmann DB, Crook S, Bedocs NM, Hoffman GS.
    Arthritis Rheum; 2001 May 15; 44(5):1149-54. PubMed ID: 11352248
    [Abstract] [Full Text] [Related]

  • 37. Novel strategies for granulocyte colony-stimulating factor treatment of severe prolonged neutropenia suggested by mathematical modeling.
    Shochat E, Rom-Kedar V.
    Clin Cancer Res; 2008 Oct 15; 14(20):6354-63. PubMed ID: 18927273
    [Abstract] [Full Text] [Related]

  • 38. Objective monitoring of activity in Wegener's granulomatosis by measurement of serum C-reactive protein concentration.
    Hind CR, Winearls CG, Lockwood CM, Rees AJ, Pepys MB.
    Clin Nephrol; 1984 Jun 15; 21(6):341-5. PubMed ID: 6467689
    [Abstract] [Full Text] [Related]

  • 39. Cost benefit and clinical efficacy of low-dose granulocyte colony-stimulating factor after standard chemotherapy in patients with non-Hodgkin's lymphoma.
    Hashino S, Morioka M, Irie T, Shiroshita N, Kawamura T, Suzuki S, Iwasaki H, Umehara S, Kakinoki Y, Kurosawa M, Kahata K, Izumiyama K, Kobayashi H, Onozawa M, Takahata M, Fujisawa F, Kondo T, Asaka M.
    Int J Lab Hematol; 2008 Aug 15; 30(4):292-9. PubMed ID: 18665826
    [Abstract] [Full Text] [Related]

  • 40. Less toxicity by optimizing chemotherapy, but not by addition of granulocyte colony-stimulating factor in children and adolescents with acute myeloid leukemia: results of AML-BFM 98.
    Creutzig U, Zimmermann M, Lehrnbecher T, Graf N, Hermann J, Niemeyer CM, Reiter A, Ritter J, Dworzak M, Stary J, Reinhardt D.
    J Clin Oncol; 2006 Sep 20; 24(27):4499-506. PubMed ID: 16983120
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 7.